Saturday, October 3, 2026
21.3 C
Bengaluru

Pharma GCCs in India — Hype, Reality & What’s Next?

Part 1: Pharma GCCs in India — Orange Markets of Nagpur?

One has to travel to Nagpur and see for oneself the Orange Markets, as I did every month during my days as the Area Sales Head for Western India. The sheer size, quantity and variety and colors are astounding. Nagpur is also known as the "Orange City". So when I read a LinkedIn post likening Pharma GCCs to Nagpur Orange Market, it really caught my attention and ignited my nostalgia for the sweet memories of the difficult to navigate orange markets of Nagpur. Santra has many meanings in Indian lingo. But that's atopic for another day.

Coming to Pharma GCCs, for years now, the Global Capability Center (GCC) phenomenon has been sold as India’s next big growth engine. From industry associations pushing the FDI story to advisory firms monetizing “India setup strategies,” the optics have been perfect. But for pharma service providers, the reality is a little less exciting.

The Pain Points That Haven’t Gone Away

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

With over three decades of experience in the pharmaceutical...

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

India’s anaemia challenge is not simply about access to...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

Topics

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

A Tale of Two Cities: Peptides and Prescriptions

What our health choices reveal about education, access and...

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

MedicinMan Intelligent Insights When Air India CEO Tewolde Gebremariam...
spot_img

Related Articles

spot_imgspot_img